GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ClearPoint Neuro Inc (NAS:CLPT) » Definitions » ROC (Joel Greenblatt) %

ClearPoint Neuro (ClearPoint Neuro) ROC (Joel Greenblatt) % : -158.28% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is ClearPoint Neuro ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ClearPoint Neuro's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -158.28%.

The historical rank and industry rank for ClearPoint Neuro's ROC (Joel Greenblatt) % or its related term are showing as below:

CLPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1825.49   Med: -271.78   Max: -144.23
Current: -189.31

During the past 13 years, ClearPoint Neuro's highest ROC (Joel Greenblatt) % was -144.23%. The lowest was -1825.49%. And the median was -271.78%.

CLPT's ROC (Joel Greenblatt) % is ranked worse than
75.88% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs CLPT: -189.31

ClearPoint Neuro's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 5.30% per year.


ClearPoint Neuro ROC (Joel Greenblatt) % Historical Data

The historical data trend for ClearPoint Neuro's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClearPoint Neuro ROC (Joel Greenblatt) % Chart

ClearPoint Neuro Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -237.87 -144.23 -225.28 -198.45 -212.32

ClearPoint Neuro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -175.64 -211.14 -225.20 -146.94 -158.28

Competitive Comparison of ClearPoint Neuro's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, ClearPoint Neuro's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ClearPoint Neuro's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's ROC (Joel Greenblatt) % falls into.



ClearPoint Neuro ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.424 + 8.987 + 1.557) - (1.742 + 1.175 + 2.288)
=7.763

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.211 + 7.911 + 1.91) - (1.446 + 2.613 + 2.947)
=6.026

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of ClearPoint Neuro for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-18.824/( ( (5.044 + max(7.763, 0)) + (4.953 + max(6.026, 0)) )/ 2 )
=-18.824/( ( 12.807 + 10.979 )/ 2 )
=-18.824/11.893
=-158.28 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ClearPoint Neuro  (NAS:CLPT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


ClearPoint Neuro ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of ClearPoint Neuro's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


ClearPoint Neuro (ClearPoint Neuro) Business Description

Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
Lynnette C Fallon director 108 CHERRY HILL DRIVE, BEVERLY MA 01915
Linda M. Liau director 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Mazin Sabra officer: Chief Operating Officer 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Joseph Michael Burnett director, officer: CEO and President C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
L. Jeremy Stigall officer: GM, Biologics & Drug Delivery 120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075
Danilo D'alessandro officer: Vice President, Finance 5 MUSICK, IRVINE CA 92618
Harold A Hurwitz officer: Chief Financial Officer
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Girin Pascal E R director C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Timothy T. Richards director ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103
Matthew B. Klein director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Marcio Souza director C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Voyager Therapeutics, Inc. 10 percent owner 75 HAYDEN AVENUE, LEXINGTON MA 02421
Wendelin C Maners officer: Vice President, Marketing ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103

ClearPoint Neuro (ClearPoint Neuro) Headlines